Cowen Upgrades PerkinElmer to Outperform | GenomeWeb

NEW YORK (GenomeWeb News) – Investment bank Cowen & Co. today upgraded PerkinElmer's stock, citing favorable end-market exposure and year-over-year comparisons that could result in mid-single digit revenue growth in 2014.

Analyst Doug Schenkel upgraded the company's stock to Outperform from Market Perform, and increased the price target on its shares to $47 from $35.20.

In afternoon trading on Monday, PerkinElmer's shares on the Nasdaq was up 1 percent to $41.68.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

University of Wisconsin researchers uncover a mutation linked to Mauriac syndrome, which affects some children with type 1 diabetes.

Theranos has hired executives to oversee compliance and regulatory issues, the Wall Street Journal reports.

Chinese researchers to embark on a trial using a CRISPR/Cas9-based immunotherapy next month, Nature News reports.

In Science this week: new chromatin imaging approach, and more.